Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06635954 · ClinicalTrials.gov registry record
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
A clinical trial of Cancer and Immunotherapy, sponsored by Oxford Biodynamics.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 3
- Study locations
NCT06635954 is a study of Cancer and Immunotherapy that is actively recruiting participants, run by Oxford Biodynamics. The registered enrollment target is 2,000 participants, below the 3,488-participant average among 615 other Cancer trials with a reported enrollment target (43% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06635954, a study of Cancer and Immunotherapy, is actively recruiting participants, sponsored by Oxford Biodynamics.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.
Conditions Studied
Study Locations (3)
Connecticut
- Eastern Connecticut Hematology and Oncology - Norwich
Georgia
- Cancer Center of Middle Georgia - Dublin
South Carolina
- Carolina Blood and Cancer Care Associates - Rock Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2024-05-14 |
| Est. Completion | 2027-05-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06635954
The ClinicalTrials.gov registry entry for NCT06635954 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,488-participant average among 615 other Cancer trials with a reported enrollment target (43% lower). The listed sponsor is Oxford Biodynamics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06635954 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, Georgia, South Carolina.
Frequently Asked Questions
What is clinical trial NCT06635954 about?
NCT06635954 is a clinical study titled "A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.". The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to act...
What is the current status of trial NCT06635954?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2024-05-14. Estimated completion is 2027-05-14.
What conditions does trial NCT06635954 study?
This clinical trial studies the following conditions: Cancer, Immunotherapy, PD-1, Immune Checkpoint Therapy, PD-L1.
Who is sponsoring clinical trial NCT06635954?
This trial is sponsored by Oxford Biodynamics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06635954 being conducted?
This trial has 3 study locations across Connecticut, Georgia, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.